Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novo Nordisk A/S ADR
(NY:
NVO
)
105.06
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novo Nordisk A/S ADR
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
65
66
Next >
Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy
March 21, 2024
Has Novo Nordisk's already red-hot stock become an even better buy?
Via
The Motley Fool
Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions
March 20, 2024
Eli Lilly stock is up 32% so far in 2024 and has risen 318% over three years.
Via
Benzinga
3 Biopharma Stocks Predicted to Soar in Q2 2024
March 20, 2024
These biopharma stocks can produce massive returns for Q2 based on new product releases and international treatment approvals.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
March 20, 2024
Via
Benzinga
Novo Nordisk Stock Stalls On Oprah TV Special, But Reddit Traders Believe It's 'Not Done Yet'
March 20, 2024
Retail investors are talking about a slim group of topics on Reddit this week including Novo Nordisk, weight-loss drug Ozempic and talk show host Oprah Winfrey.
Via
Benzinga
Decoding 7 Analyst Evaluations For Novo Nordisk
March 20, 2024
Via
Benzinga
Is Novo Nordisk on the Verge of Another Blockbuster Drug?
March 19, 2024
Novo Nordisk just received some positive news for its latest obesity drug, amycretin.
Via
The Motley Fool
Novo Nordisk Options Trading: A Deep Dive into Market Sentiment
March 18, 2024
Via
Benzinga
Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock?
March 20, 2024
The gap has been shrinking between these stocks over the past month.
Via
The Motley Fool
Tesla Investor Ross Gerber Backs Ozempic's Potential To Reduce Monthly Food Expenses — Less Eating, More Saving
March 20, 2024
Ross Gerber, a prominent Tesla investor, has suggested that the use of Ozempic could lead to significant cost savings.
Via
Benzinga
3 Juicy Stocks Serving Up 5% Dividends That You Can Snag for $50
March 19, 2024
These dividend stocks selling for under $50 with yields of 5% or more offer a lot to investors at any time making these strong buys.
Via
InvestorPlace
What Retail Apocalypse? 7 Stocks Proving the Doomsayers Wrong.
March 19, 2024
People have said retail is dying for years now but the supposed apocalypse is nowhere to be found with these fast-charging retail stocks.
Via
InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
March 19, 2024
Via
Benzinga
Is NYSE:NVO suited for dividend investing?
March 18, 2024
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for dividend investing?
Via
Chartmill
Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy?
March 17, 2024
The company continues to impress investors.
Via
The Motley Fool
Here's How Much $100 Invested In Novo Nordisk 10 Years Ago Would Be Worth Today
March 15, 2024
Via
Benzinga
Did Novo Nordisk Just Get a Jump on Eli Lilly?
March 19, 2024
A recent FDA announcement may have just put one company in the lead.
Via
The Motley Fool
Exposures
Product Safety
Oprah Winfrey Tackles Weight Loss Drug Stigma In Prime-Time Special Amid Wegovy-Ozempic Frenzy: 'For 25 Years, Making Fun Of My Weight Was National Sport'
March 19, 2024
Winfrey dedicated a prime-time special to discussing the stigma surrounding weight loss and the use of drugs like Ozempic and Mounjaro
Via
Benzinga
LifeMD Shares Come Back to Life on GLP-1 Business Growth
March 19, 2024
LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024
Via
MarketBeat
Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win?
March 19, 2024
Madrigal has one key advantage over its two huge potential future rivals.
Via
The Motley Fool
Exposures
Product Safety
Inconsistent Insurance Coverage For Weight Loss Drugs - Novo Nordisk's GLP-1s Face Hurdles Despite Health Benefits
March 18, 2024
Debate ensues over insurance coverage for Novo Nordisk's Wegovy following FDA approval. Evernorth's EncircleRx introduces financial guarantee, aiming to control costs and improve accessibility....
Via
Benzinga
Exposures
Product Safety
US Prescriptions Race For Weight Loss Drugs - Eli Lilly's Zepbound Overtakes Novo Nordisk's Wegovy
March 18, 2024
Latest in weight-loss medication trends: Eli Lilly And Co's Zepbound (tirzepatide) surges past rival Novo Nordisk A/S's Wegovy (semaglutide) in new prescriptions, signaling a shift in the obesity...
Via
Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Exhibits Quality Stock Traits. Here's Why.
March 18, 2024
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) should be investigated by quality investors.
Via
Chartmill
Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be
March 17, 2024
The drugmaker is magnificent in its own right.
Via
The Motley Fool
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
March 17, 2024
There's no need for delays in buying these great stocks.
Via
The Motley Fool
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
March 17, 2024
Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.
Via
The Motley Fool
Eli Lilly Taps Amazon to Deliver Its Weight Management Blockbuster. Is It Time to Buy the Pharma Stock?
March 17, 2024
Free two-day shipping for Prime members and a direct-to-consumer sales model could accelerate sales of Eli Lilly's Zepbound.
Via
The Motley Fool
7 Mega-Cap Stocks That Can Turn $10,000 Into $1 Million
March 15, 2024
These million dollar mega-cap stocks will continue to produce big winners in 2024 and beyond as they continue to rise.
Via
InvestorPlace
Novo Nordisk Just Scored a Huge Win. And It's Not Related to Ozempic
March 15, 2024
Novo Nordisk might be best known for Ozempic, but the company just received positive news from the FDA for an entirely different drug.
Via
The Motley Fool
Exposures
Product Safety
3 Weight-Loss Stocks to Buy as GLP-1 Mania Takes Hold
March 15, 2024
If you want to take advantage of the red-hot growth in weight-loss stocks, these are three companies that you can own a piece of today.
Via
InvestorPlace
< Previous
1
2
...
21
22
23
24
25
26
27
28
29
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.